Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows

BURLINGTON, N.C. , June 17, 2024 /PRNewswire/ — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp Global Trial Connect, a suite of central laboratory solutions aimed at increasing the speed of clinical trials where the heart of clinical research is conducted – investigator sites.

“The patient-investigator-biopharma sponsor relationship is at the foundation of a successful clinical trial. Global Trial Connect simplifies the investigator workflow, improves the patient experience and ultimately enables biopharma sponsors to bring therapies to market faster,” said Jon DiVincenzo, EVP and President, Central Laboratories and International at Labcorp.  “As the world’s leading central laboratory, Labcorp is dedicated to improving the pace of clinical trials focusing on the investigator site experience from study initiation to patient recruitment and data collection.”

Labcorp Global Trial Connect, available to current Labcorp Central Laboratory clients, incorporates complementary digital and data solutions that help accelerate clinical study startup, maintain study momentum and increase study throughput. Capabilities include:

  • Site enablement resources – to identify new study opportunities, enhance patient access and recruitment and improve diversity in clinical trials.
  • Supply readiness support – to increase study startup efficiencies, reduce trial delays and reduce supply and kit waste.
  • Site workflow facilitation – to help integrate sample collection and tracking data, provide visibility and actionable analytics to both sites and sponsors, and reduce errors, queries, holds and data revisions through eRequisition functionality.
  • Study management and investigator support – to accelerate study startup and maintain study momentum with 24/7 site support and on-demand tools and trainings.

For more information, visit LabcorpGlobalTrialConnect.com.

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company’s more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-launches-global-trial-connect-to-accelerate-clinical-trials-302174129.html

SOURCE Labcorp

Staff

Recent Posts

AI-Era Position Statement to Protect the Integrity of Healthcare, Technology, and Services Benchmarking published by Black Book Research

Black Book outlines an AI-era integrity architecture for healthcare benchmarking, instrumentation hardening, tiered verification, real-time…

21 hours ago

New employee representative on the Board of Directors of Novo Nordisk A/S

Bagsværd, Denmark, 31 January 2026 – Thomas Rantzau, employee representative on the Board of Directors since…

21 hours ago

Embers to Empowerment: The Womb Room Reopens in Govans, Expanding Community-Centered Perinatal Care After Hampden Fire

Baltimore, Maryland, Jan. 31, 2026 (GLOBE NEWSWIRE) -- After sustaining water damage during the massive…

21 hours ago

Oxford Healthspan to Introduce New Primeadine® GF Powder Through a ‘Longevity Shot’ Experience During Grammy Week in Los Angeles

Science-Backed Spermidine Ritual Brings Cellular Renewal to a High-Performance Cultural Moment Primeadine Longevity Shot Primeadine…

21 hours ago

Enzon Announces Commencement of Exchange Offer Relating to Series C Non-Convertible Redeemable Preferred Stock in Connection With Viskase Merger

CRANFORD, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Enzon Pharmaceuticals, Inc. (OTCQB: ENZN) (“Enzon” or…

21 hours ago

Park Dental Partners Announces Dates for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

MINNEAPOLIS, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Park Dental Partners, Inc. (NASDAQ: PARK), a leading…

21 hours ago